solomo.ai

Alembic Ltd (ALEMBICLTD) — shareholding pattern, promoter holding, financials and share price

About Alembic Ltd (ALEMBICLTD)

Alembic Ltd operates in the Residential, Commercial Projects industry, within the Realty sector. It trades on the NSE as ALEMBICLTD and on the BSE under scrip code 506235. Its ISIN is INE426A01027.

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group. With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited. [1]

Alembic Limited is a veteran manufacturer of bulk drugs and pharmaceuticals for human and animal healthcare in India. Founded in 1907, it has developed strong expertise in APIs and formulations, with significant production facilities in Vadodara and Solan.

Alembic's history of pharmaceutical innovation includes significant developments such as the launch of Erythromycin under Althrocin in 1972, which became a bestseller in India by 1997.

Listed peers in Residential, Commercial Projects: Elpro International Ltd, Hubtown Ltd, Arvind SmartSpaces Ltd, Marathon Nextgen Realty Ltd, Ajmera Realty & Infra India Ltd, Arkade Developers Ltd.

Valuation & Returns

10 Jul 2026

At ₹89.99 a share on 10 Jul 2026, Alembic Ltd (ALEMBICLTD) was valued at a price-to-earnings ratio of 18.35x and a price-to-book of 0.99x on a book value of ₹91.07 per share as of Mar 2025. Solomo computes return on equity of 5.39% and return on capital employed of 6.42% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
18.35x
P/B
0.99x
EPS (TTM)
₹4.9
Book value / share
₹91.07
ROE
5.39%
ROCE
6.42%
ROA
5.03%
Debt / equity
0.01x
Dividend yield
2.67%
EBITDA margin
41.99%
52-week range
₹86 – ₹177.5

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Alembic Ltd (ALEMBICLTD) reported revenue of ₹240 crore, net profit of ₹317 crore and earnings per share of ₹12.36. That compares with revenue of ₹222 crore and net profit of ₹311 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹60 crore and net profit ₹67 crore (consolidated).

Consolidated annual results for Alembic Ltd (ALEMBICLTD), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)78127157222240
Net profit (₹ cr)222191269311317
EPS (₹)8.657.4210.4612.112.36
Compound annual growth for Alembic Ltd (ALEMBICLTD). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth5.35%23.81%41.31%40.89%
Profit growth21.43%8.70%18.31%55.67%
Stock price CAGR11%-8%5%-26%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 70.88% of Alembic Ltd (ALEMBICLTD) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.25% and domestic institutional investors (DII) hold 0.05%. Market capitalisation was ₹2,311 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.

Largest disclosed public shareholders in Jun 2026: INVESTORS EDUCATION AND PROTECTION FUND 1.31%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202670.88%-1.25%0.05%29.12%
Mar 202670.88%-1.25%0.05%29.12%
Dec 202570.88%-1.28%0.05%29.12%
Sep 202570.88%-1.38%0.05%29.12%
Jun 202570.88%-1.5%0.05%29.12%
Mar 202570.88%-1.66%0.05%29.12%
Dec 202470.88%-1.78%0.06%29.12%
Sep 202470.88%-1.97%0.09%29.12%
Every quarter since Mar 2001 Filing data, not investment advice.